The BCL2L11 Knockout A2780 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the BCL2L11 gene in the A2780 human ovarian cancer cell line. BCL2L11 encodes BIM, a pro-apoptotic BH3-only protein that serves as a critical sensor and executor of intrinsic apoptosis. This loss-of-function model enables researchers to investigate BIM-dependent apoptotic signaling and its role in cancer biology, particularly in the context of ovarian carcinoma. By leveraging polyclonal pools, the product preserves heterogeneous editing events while maintaining the overall genomic context of the A2780 background, facilitating robust population-level functional studies without clonal artifacts.
The A2780 cell line, derived from an untreated patient with human ovarian endometrioid adenocarcinoma, represents a well-characterized model for ovarian cancer research. It is widely employed in studies of cisplatin sensitivity and acquired drug resistance, making it particularly valuable for dissecting chemotherapeutic response mechanisms. The A2780 background exhibits intact apoptotic machinery, and its use in gene perturbation experiments allows for clear interpretation of BIM’s contribution to drug-induced cell death. These cells are adherent, maintain epithelial morphology, and are amenable to standard transfection and lentiviral transduction protocols, ensuring compatibility with diverse experimental workflows.
BIM functions at the nexus of intrinsic apoptosis by neutralizing anti-apoptotic BCL-2 family members, including BCL-2, BCL-XL, and MCL-1, and by potentially directly activating the pore-forming effectors BAX and BAK. This activity promotes mitochondrial outer membrane permeabilization, cytochrome c release, apoptosome assembly, and subsequent caspase-9/3 activation. BIM expression is transcriptionally regulated by FOXO3a, MYC, and E2F1, and its activity is modulated by ERK/MAPK-mediated phosphorylation, which targets BIM for proteasomal degradation. Additionally, BIM interacts with dynein light chain LC8, linking apoptotic signaling to the cytoskeleton. Disruption of BCL2L11 ablates these interactions, providing a clean background to dissect the hierarchical activation of apoptosis.
In the A2780 ovarian cancer context, BCL2L11 knockout allows targeted interrogation of BIM’s role in mediating responses to platinum-based chemotherapeutics and BH3-mimetic agents. BIM is frequently implicated in cisplatin-induced apoptosis, and its loss or suppression can contribute to drug resistance. This polyclonal knockout model thus serves as a powerful tool for studying mechanisms of intrinsic and acquired resistance, identifying synthetic lethal interactions, and evaluating strategies to re-sensitize resistant tumors. It is especially relevant for research on ovarian cancer, where BIM expression often correlates with patient survival and treatment efficacy.
Research applications include mechanistic studies of apoptotic signaling, functional validation of BIM, and screening for compounds restoring apoptosis in BIM-deficient cancers. Typical assays encompass Western blotting for BIM and cleaved caspase-3, Annexin V/PI apoptosis analysis, RT-qPCR, flow cytometry for mitochondrial membrane potential, co-immunoprecipitation, and cell viability assays (MTT, CellTiter-Glo). BH3 profiling and drug sensitivity testing with cisplatin or BH3 mimetics are readily performed. For more information, contact Ascent Research.
